Time on boards
- Boards served
- 3
- Current seats
- 3
- Board service
- 8 years
- Director since
- 2023
8 years of board service in total across 3 boards, counting each seat separately. Longest: NeoGenomics Inc., 3 years.
NeoGenomics Inc.
Director
Rhythm Pharmaceuticals Inc.
Director
Alumis Inc.
Director
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Alumis Inc. June 30, 202699.7%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 30, 2026 | Alumis Inc. | Grant or award | +3,553 | — | — |
| Jun 23, 2026 | Rhythm Pharmaceuticals Inc. | Option exercise | +4,712 | — | — |
| Jun 22, 2026 | Rhythm Pharmaceuticals Inc. | Option exercise | +37,000 | $28.27 | $1,045,990 |
| Jun 22, 2026 | Rhythm Pharmaceuticals Inc. | Open-market sale | −37,000 | $100.32 | $3,711,840 |
| Jun 15, 2026 | NeoGenomics Inc. | Open-market sale | −5,307 | $11.10 | $58,908 |
| Jun 9, 2026 | NeoGenomics Inc. | Open-market sale | −5,307 | $11.29 | $59,916 |
| Jun 1, 2026 | NeoGenomics Inc. | Option exercise | +23,077 | — | — |
| Jun 18, 2025 | Rhythm Pharmaceuticals Inc. | Option exercise | +4,000 | — | — |
| Jun 1, 2025 | NeoGenomics Inc. | Option exercise | +12,254 | — | — |
| May 9, 2025 | NeoGenomics Inc. | Open-market purchase | +7,000 | $8.14 | $56,980 |
| Sep 10, 2024 | Rhythm Pharmaceuticals Inc. | Option exercise | +10,000 | $4.15 | $41,500 |
| Sep 10, 2024 | Rhythm Pharmaceuticals Inc. | Option exercise | +7,501 | $18.99 | $142,444 |
| Sep 10, 2024 | Rhythm Pharmaceuticals Inc. | Open-market sale | −8,490 | $49.05 | $416,435 |
| Sep 10, 2024 | Rhythm Pharmaceuticals Inc. | Open-market sale | −8,661 | $50.20 | $434,782 |
| Sep 10, 2024 | Rhythm Pharmaceuticals Inc. | Open-market sale | −350 | $50.60 | $17,710 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.